Maravai LifeSciences Q3 revenue misses estimates on weakness in nucleic acid segment

Maravai Lifesciences Holdings

06/11/2025 21:22

Overview

Maravai Q3 revenue falls 39.7% yr/yr, missing analyst expectations

Adjusted EBITDA for Q3 misses analyst estimates, reflecting operational challenges

Biologics Safety Testing revenue grows 7.2% yr/yr, driven by strong product lines

Outlook

Maravai expects full-year 2025 revenue to be approximately $185 mln

Company anticipates TriLink to achieve double-digit sequential revenue growth in Q4 2025

Maravai aims for attractive financial results in Q4 2025 and 2026

Result Drivers

NUCLEIC ACID PRODUCTION - Revenue decreased 52.9% due to lack of high-volume CleanCap orders and non-recurring large GMP orders

BIOLOGICS SAFETY TESTING - Revenue increased 7.2% due to strength in nearly all product lines

RESTRUCTURING AND COST REDUCTION - Organizational restructuring and cost reduction initiatives are on track, expected to improve future financial results

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
$41.60 mln
$49.003 mln (11 Analysts)
Q3 Net Income
-$45.10 mln
Q3 Adjusted EBITDA
Miss
-$10.80 mln
-$7.41 mln (10 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Maravai LifeSciences Holdings Inc is $4.50, about 36.2% above its November 5 closing price of $2.87

Press Release: ID:nBwFVVXFa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)